SCHEMBL5544677

SCHEMBL5544677

Brc1ccc(CN[CH]c2ccccc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.45
ADH1B P00325 1/20 0.44
ADH1C P00326 1/20 0.44
ADH1A P07327 1/20 0.44
ADH7 P40394 1/20 0.44
KDM1A O60341 1/20 0.42
BCHE P06276 1/20 0.40
ACHE P22303 1/20 0.40
BACE1 P56817 1/20 0.40
APP P05067 2/20 0.40
TGM2 P21980 1/20 0.40
PYCR1 P32322 1/20 0.39
ALDH1A1 P00352 4/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 1/20 0.39
HPGD P15428 1/20 0.39
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
AGER Q15109 1/20 0.38
G6PD P11413 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7385255 0.86 ADH1B (0.58) ADH1BADH1CADH1AADH7ALDH1A1
SCHEMBL5546127 0.81 ADH1B (0.44) ADH1BADH1CADH1AADH7APP
SCHEMBL5534736 0.81 PLA2G1B (0.49) ADH1BADH1CADH1AADH7KDM1A
SCHEMBL5542584 0.81 SMN1; SMN2 (0.49) L3MBTL1ADH1BADH1CADH1AADH7
SCHEMBL5539505 0.81 LMNA (0.50) L3MBTL1ADH1BADH1CADH1AADH7
SCHEMBL5541612 0.80 KDM1A (0.47) ADH1BADH1CADH1AADH7KDM1A
SCHEMBL5537515 0.77 RAB9A (0.48) L3MBTL1ADH1BADH1CADH1AADH7
SCHEMBL5544473 0.77 RAB9A (0.57) KDM1AALDH1A1HTTTDP1
SCHEMBL5539678 0.73 KDM1A (0.42) L3MBTL1KDM1AALDH1A1LMNAHPGD
SCHEMBL5535940 0.73 KDM1A (0.47) ADH1BADH1CADH1AADH7KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 L3MBTL1 1931/4885ADH1B 281/4885ADH1C 285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.